Phase II study of sodium valproate in combination with oral etoposide in platinum-resistant ovarian cancer

被引：0
|
作者：
Thejeswar, N. [1 ]
Goenka, L. [1 ]
Dubashi, B. [1 ]
Kayal, S. [1 ]
Jayanthi, M. [2 ]
Barathi, D. [3 ]
Ganesan, P. [1 ]
机构：
[1] JIPMER Jawaharlal Inst Postgrad Med Educ & Res, Med Oncol, Pondicherry, India
[2] JIPMER Jawaharlal Inst Postgrad Med Educ & Res, Clin Pharmacol, Pondicherry, India
[3] JIPMER Jawaharlal Inst Postgrad Med Educ & Res, Radiodiag, Pondicherry, India
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷
关键词：
D O I：
10.1016/j.annonc.2022.10.227
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
191P
引用
收藏
页码：S1510 / S1510
页数：1
相关论文
共 50 条
  • [1] Phase II study of sodium valproate in combination with oral etoposide in platinum-resistant ovarian cancer
    Nakka, Thejeswar
    Goenka, Luxitaa
    Dubashi, Biswajit
    Kayal, Smita
    Mathaiyan, Jayanthi
    Barathi, Deepak
    Krishnamoorthy, Narendran
    Thumaty, Divya Bala
    Dahagama, Sindhu
    Ganesan, Prasanth
    MEDICAL ONCOLOGY, 2022, 39 (12)
  • [2] Phase II study of sodium valproate in combination with oral etoposide in platinum-resistant ovarian cancer
    Thejeswar Nakka
    Luxitaa Goenka
    Biswajit Dubashi
    Smita Kayal
    Jayanthi Mathaiyan
    Deepak Barathi
    Narendran Krishnamoorthy
    Divya Bala Thumaty
    Sindhu Dahagama
    Prasanth Ganesan
    Medical Oncology, 39
  • [3] PROTRACTED ORAL ETOPOSIDE IN EPITHELIAL OVARIAN-CANCER - A PHASE-II STUDY IN PATIENTS WITH RELAPSED OR PLATINUM-RESISTANT DISEASE
    SEYMOUR, MT
    MANSI, JL
    GALLAGHER, CJ
    GORE, ME
    HARPER, PG
    EVANS, TRJ
    EDMONDS, PM
    SLEVIN, ML
    BRITISH JOURNAL OF CANCER, 1994, 69 (01) : 191 - 195
  • [4] Phase II study of the combination of pegylated liposomal doxorubicin and topotecan in platinum-resistant ovarian cancer
    Verhaar-Langereis, M
    Karakus, A
    Van Eijkeren, M
    Voest, E
    Witteveen, E
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2006, 16 (01) : 65 - 70
  • [5] ORAL ETOPOSIDE IS ACTIVE AGAINST PLATINUM-RESISTANT EPITHELIAL OVARIAN-CANCER
    HOSKINS, PJ
    SWENERTON, KD
    JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (01) : 60 - 63
  • [6] Oral treosulfan as second-line treatment in platinum-resistant ovarian cancer: A phase II study
    Keldsen, N
    Madsen, EL
    Havsteen, H
    Kamby, C
    Laursen, L
    Sandberg, E
    GYNECOLOGIC ONCOLOGY, 1998, 69 (02) : 100 - 102
  • [7] Second-Line Treatment with Intravenous Gemcitabine and Oral Etoposide in Platinum-Resistant Advanced Ovarian Cancer Patients: Results of a Phase II Study
    Bruzzone, M.
    Centurioni, M. G.
    Giglione, P.
    Gualco, M.
    Merlo, D. F.
    Miglietta, L.
    Cosso, M.
    Giannelli, F.
    Cristoforoni, P.
    Ferrarini, M.
    ONCOLOGY, 2011, 80 (3-4) : 238 - 246
  • [8] Altretamine (hexamethylmelamine) in the treatment of platinum-resistant ovarian cancer: a phase II study
    Keldsen, N
    Havsteen, H
    Vergote, I
    Bertelsen, K
    Jakobsen, A
    GYNECOLOGIC ONCOLOGY, 2003, 88 (02) : 118 - 122
  • [9] Oral etoposide (VP16) in platinum-resistant epithelial ovarian cancer (EOC)
    Alici, S
    Saip, P
    Eralp, YI
    Aydiner, A
    Topuz, E
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2003, 26 (04): : 358 - 362
  • [10] Oral Etoposide for Platinum-Resistant and Recurrent Epithelial Ovarian Cancer: a Study by the Anatolian Society of Medical Oncology
    Kucukoner, Mehmet
    Isikdogan, Abdurrahman
    Yaman, Sebnem
    Gumusay, Ozge
    Unal, Olcun
    Ulas, Arife
    Elkiran, Emir T.
    Kaplan, Muhammed A.
    Ozdemir, Nuriye
    Inal, Ali
    Urakci, Zuhat
    Buyukberber, Suleyman
    ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2012, 13 (08) : 3973 - 3976
12345